Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The inflammatory storm in critically ill patients releases cytokines, causing systemic immune damage, which may be an important cause of multiple organ failure and even death. Inflammatory storms exacerbate the deterioration of the disease in those children. Gamma globulin may be an effective option to control inflammatory storms. However, this preliminary result needs to be verified from reliable and representative RCTs. In our study, we conducted a retrospective study on the use of gamma globulin and an unused control group. At present, the indications of IVIG are mainly focused on the neuromuscular system and the blood system. We hope to establish a more appropriate and operable evaluation table for the suitability of gamma globulin for clinical use.
In severe infective patients who survive the initial inflammatory storm, the immune response often evolves toward a state of immunosuppression, which contributes to increased mortality and severe secondary hospital-acquired infections. However, the role of gamma globulin therapy in patients with severe infection including sepsis and septic shock is discussed controversially. We intend to retrospectively analyze the efficacy and application evaluation of gamma globulin in severely infected children hospitalized in the intensive care unit. Clinical and demographic data, as well as treatment outcome will be collected from the electronic health record. It is expected to provide evaluation basis for clinicians to formulate treatment plans and clinical pharmacists for special comments on the clinical use of gamma globulin.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| trial group | Human Gamma Globulin | ||
| control group | conventional treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| The death rate of children | The death rate of children in 28 days after their discharged from PICU | within 28 days after they discharged from PICU |
| length of stay in PICU | Time from PICU admission to discharge | up to 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| CD4+/CD8+ | levels of peripheral blood subgroup of T lymphocyte (digital form) | Within 3 to 15 days after the start of treatment |
| C-reactive protein (CRP) | C-reactive protein (digital form) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
All children hospitalized in PICU of Children's Hospital of Fudan University from January 2022 to December 2023
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Guoping Lu, Doctor | Contact | 13788904150 | 13788904150@163.com | |
| Yao Wang | Contact | +86 13636547582 | y_wang@fudan.edu.cn |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Children's Hospital of Fudan University | Recruiting | Shanghai | Shanghai Municipality | China |
Not provided
| ID | Term |
|---|---|
| D016638 | Critical Illness |
| D018805 | Sepsis |
| ID | Term |
|---|---|
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| Within 3 to 15 days after the start of treatment |
| IL-2R | The interleukin-2 receptor (digital form) | Within 3 to 15 days after the start of treatment |
| TNF-alpha | Tumor necrosis factor alpha (digital form) | Within 3 to 15 days after the start of treatment |
| Treg | levels of peripheral blood subgroup of T lymphocyte (digital form) | Within 3 to 15 days after the start of treatment |
| IL-6 | The interleukin-6 (digital form) | Within 3 to 15 days after the start of treatment |
| IFN-gamma | Interferon gamma (digital form) | Within 3 to 15 days after the start of treatment |
| Procalcitonin (digital form) | Procalcitonin (digital form) | Within 3 to 15 days after the start of treatment |
| IL-10 | The interleukin-10 (digital form) | Within 3 to 15 days after the start of treatment |
| Children's Hospital of Fudan University | Recruiting | Shanghai | 201102 | China |
|
| D018746 | Systemic Inflammatory Response Syndrome |
| D007249 | Inflammation |